Unknown

Dataset Information

0

The formation of cortical actin arrays in human trabecular meshwork cells in response to cytoskeletal disruption.


ABSTRACT: The cytoskeleton of human trabecular meshwork (HTM) cells is known to be altered in glaucoma and has been hypothesized to reduce outflow facility through contracting the HTM tissue. Latrunculin B (Lat-B) and Rho-associated protein kinase (ROCK) inhibitors disrupt the actin cytoskeleton and are in clinical trials as glaucoma therapeutics. We have previously reported a transient increase in HTM cell stiffness peaking at 90 min after Lat-B treatment with a return to pretreatment values after 270 min. We hypothesize that changes in actin morphology correlate with alterations in cell stiffness induced by Lat-B but this is not a general consequence of other cytoskeletal disrupting agents such as Rho kinase inhibitors. We treated HTM cells with 2 µM Lat-B or 100 µM Y-27632 and allowed the cells to recover for 30-270 min. While examining actin morphology in Lat-B treated cells, we observed striking cortical actin arrays (CAAs). The percentage of CAA positive cells (CPCs) was time dependent and exceeded 30% at 90 min and decreased after 270 min. Y-27632 treated cells exhibited few CAAs and no changes in cell stiffness. Together, these data suggest that the increase in cell stiffness after Lat-B treatment is correlated with CAAs.

SUBMITTER: Murphy KC 

PROVIDER: S-EPMC4178168 | biostudies-literature | 2014 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

The formation of cortical actin arrays in human trabecular meshwork cells in response to cytoskeletal disruption.

Murphy Kaitlin C KC   Morgan Joshua T JT   Wood Joshua A JA   Sadeli Adeline A   Murphy Christopher J CJ   Russell Paul P  

Experimental cell research 20140630 1


The cytoskeleton of human trabecular meshwork (HTM) cells is known to be altered in glaucoma and has been hypothesized to reduce outflow facility through contracting the HTM tissue. Latrunculin B (Lat-B) and Rho-associated protein kinase (ROCK) inhibitors disrupt the actin cytoskeleton and are in clinical trials as glaucoma therapeutics. We have previously reported a transient increase in HTM cell stiffness peaking at 90 min after Lat-B treatment with a return to pretreatment values after 270 mi  ...[more]

Similar Datasets

| S-EPMC3220413 | biostudies-literature
| S-EPMC4553930 | biostudies-literature
| S-EPMC10309047 | biostudies-literature
| S-EPMC8500954 | biostudies-literature
| S-EPMC4509060 | biostudies-literature
| S-EPMC5359060 | biostudies-literature
| S-EPMC4015974 | biostudies-literature
| S-EPMC8700223 | biostudies-literature
| S-EPMC3003706 | biostudies-literature
| S-EPMC3536900 | biostudies-literature